Antiviral chemotherapy.
The above discussion is not intended to be exhaustive but rather to discuss several compounds which are particularly promising at this time. There is no question that great strides have been made in the development of antiviral compounds over the past couple of decades. Many questions remain unanswered such as long-term effects on the host, possible emergence of resistant viruses, optimal routes of administration, and the proper regimens for particular viruses and diseases. In addition, current studies are evaluating combinations of antiviral agents as well as combination therapy involving interferon or antibody or immunity stimulants along with an antiviral agent. Surprising progress has been made to date resulting not only in new therapeutic modalities but promising a new era of progress.
D000212:Acyclovir / Q000494:pharmacology / Q000627:therapeutic use; D000547:Amantadine / Q000494:pharmacology / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use*; D004267:DNA Viruses / Q000187:drug effects; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D012328:RNA Viruses / Q000187:drug effects; D012254:Ribavirin / Q000494:pharmacology / Q000627:therapeutic use; D014740:Vidarabine / Q000494:pharmacology / Q000627:therapeutic use; D014777:Virus Diseases / Q000188:drug therapy
D000998:Antiviral Agents; D012254:Ribavirin; D000547:Amantadine; D014740:Vidarabine; D000212:Acyclovir